Health Care Counsel Blog

794 total results. Page 1 of 32.

Stephanie Trunk, Shoshana Golden
Earlier this month, the US District Court for the District of Oregon issued a declaratory judgment invalidating a key component of the Oregon Drug Price Transparency Program.
Cissy Jackson, Daniel Sjostedt*
As we predicted at the end of the 117th Congress, 2023 was a year of progress for advocates of Pharmacy Benefit Manager (PBM) reform.
D. Jacques Smith, Randall A. Brater, Michael F. Dearington, Nadia Patel, Mattie Bowden, Heather M. Zimmer
Headlines that Matter for Companies and Executives in Regulated Industries
Shoshana Golden, Richard J. Berman
The top legal issues in 2024 for the life sciences field reflect the complex and changing legal landscape that the industry is navigating, encompassing drug pricing, regulatory challenges, and broader societal and governance concerns.
D. Jacques Smith, Randall A. Brater, Mohammed T. Farooqui, Heather M. Zimmer
Headlines that Matter for Companies and Executives in Regulated Industries
Jill A. Steinberg, Shoshana Golden, D. Austin Rettew
On January 30, a federal jury found six people guilty of federal civil rights offenses arising from their participation in a blockade of a reproductive health care clinic in Mount Juliet, Tennessee.
Caroline Turner English, Pascal Naples, D. Austin Rettew
In a recent opinion, E.W. v. Health Net Life Insurance Co., the US Court of Appeals for the Tenth Circuit clarified the elements that plaintiffs must plead to state claims under the Mental Health Parity and Addiction Equity Act (MHPAEA).
David S. Greenberg, Douglas A. Grimm, Stephanie Trunk, Jill A. Steinberg, Hillary M. Stemple, Gayland O. Hethcoat II, D. Jacques Smith, Dan H. Renberg, Alison Lima Andersen, Jessica Sprovtsoff, Moyosore O. Koya, Shoshana Golden, D. Austin Rettew, Rebekkah R.N. Stoeckler, Oliver Spurgeon III*
With the 2024 underway, ArentFox Schiff highlights 10 of the most pressing legal issues facing the health care industry this year.
Robert B. Koonin, Cynthia Thomas, Jo-Ann Marchica, Mindy Pittell Hurwitz
Could 2024 bring renewed growth for the skilled nursing and senior housing market or will proposed regulatory changes and the lingering effects of COVID-19 stymie hopes for a potential rebound?
Caroline Turner English, Alison Lima Andersen, D. Austin Rettew, David S. Greenberg, Jack R. Bierig, Aphrodite Kokolis
On December 18, 2023, the US Departments of Treasury, Labor, and Health and Human Services (the Departments) issued a rule finalizing the 2024 non-refundable administrative fee parties must pay to access the arbitration process established under the No Surprises Act (the Act).
D. Jacques Smith, Randall A. Brater, Michael F. Dearington, Nadia Patel, Laura Zell
Headlines that Matter for Companies and Executives in Regulated Industries
Berin S. Romagnolo, Nancy A. Noonan
Most foreign nationals living in the United States in temporary status (not green card holders) can only reenter the United States after international travel if they have a current visa in their passport.
Gayland O. Hethcoat II, Moyosore O. Koya, D. Reed Freeman Jr.
The US Department of Health and Human Services (HHS) and Federal Trade Commission (FTC) have distinct yet intersecting roles in regulating business practices involving individuals’ health information.
Stephanie Trunk
The Centers for Medicare and Medicaid Services (CMS) continues to take steps implementing the Inflation Reduction Act of 2022 (IRA). Newly revised guidance issued on December 14, 2023, makes notable changes and clarifications to CMS’ previous guidance released earlier this year.
D. Jacques Smith, Randall A. Brater, Michael F. Dearington, Nadia Patel, Elizabeth Satarov, Heather M. Zimmer
Headlines that Matter for Companies and Executives in Regulated Industries
David S. Greenberg, D. Austin Rettew
With the surge of interest in artificial intelligence (AI), it should be no surprise that health insurers have come under scrutiny concerning their use of AI predictive tools to deny medical insurance claims.
D. Jacques Smith, Randall A. Brater, Michael F. Dearington, Nadia Patel, Mattie Bowden, D. Austin Rettew
Headlines that Matter for Companies and Executives in Regulated Industries
Gayland O. Hethcoat II, Moyosore O. Koya
With the recent passage of Assembly Bill (AB) 254 and AB 1697, California’s Confidentiality of Medical Information Act (CMIA) will extend privacy protections to reproductive and sexual health information on mobile applications and internet websites.
Jeffrey E. Rummel
The event will be held on November 17, 2023, to explore the intersection of broadband connectivity and maternal health.
Stephanie Trunk, Wayne H. Matelski, Kevin R. Pinkney, Brian P. Waldman
Here we are in fourth quarter of 2023 already! As companies start wrapping up 2023 and preparing and modeling for 2024, we thought it was a good time to highlight five regulatory developments, changes, or challenges on the horizon for pharmaceutical manufacturers operating in the US market:
D. Jacques Smith, Randall A. Brater, Michael F. Dearington, Nadia Patel, Morgan R. Pankow, Mattie Bowden
Headlines that Matter for Companies and Executives in Regulated Industries
Jeffrey E. Rummel
The Federal Communications Commission (FCC) has launched a comprehensive inquiry designed to explore ways the Commission’s Mapping Broadband Health in America platform could be expanded and enhanced to help better leverage digital health tools to improve maternal care.
Jack R. Bierig, Shoshana Golden, Wayne H. Matelski
On October 3, the US Food and Drug Administration (FDA) issued a proposed rule regarding the regulation of in vitro diagnostic products (IVDs).
Caroline Turner English, Alison Lima Andersen, D. Austin Rettew, David S. Greenberg, Jack R. Bierig, Aphrodite Kokolis
On September 21, 2023, the US Departments of Treasury (DOT), Labor (DOL), and Health and Human Services (HHS) (the Departments) issued new rulemaking governing the administrative fee required to access the arbitration process established under the No Surprises Act (the Act). Under the proposed rule, the new fee would be set at $150.
Douglas A. Grimm, Moyosore O. Koya
On September 12, 2023, the Senate Judiciary Subcommittee on Privacy, Technology, and the Law convened a hearing to discuss potential legislation focused on AI models, the third in a series of hearings by the subcommittee analyzing issues in AI oversight. A key discussion topic was the Bipartisan Framework for US AI Act introduced by Senators Richard Blumenthal and Josh Hawley.